Bromocriptine (mesylate)

Bromocriptine (mesylate)

• Product Name Alternative: CB-154
• CAS Number: 22260-51-1
• UNSPSC Description: Bromocriptine mesylate is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pKi of 8.05±0.2.
• Target Antigen: Autophagy; Dopamine Receptor
• Type: Reference compound
• Related Pathways: Autophagy;GPCR/G Protein;Neuronal Signaling
• Field of Research: Neurological Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Bromocriptine-mesylate.html
• Purity: 99.98
• Solubility: DMSO : 175 mg/mL (ultrasonic)|H2O : 1.1 mg/mL (ultrasonic;adjust pH to 3 with HCl)
• Smiles: [H][C@@]12CC3=C(Br)NC4=CC=CC(C1=C[C@@H](C(N[C@@]5(C(C)C)C(N6[C@@H](CC(C)C)C(N7CCC[C@]7([C@]6(O)O5)[H])=O)=O)=O)CN2C)=C43.OS(=O)(C)=O
• Molecular Weight: 750.70
• References & Citations: [1]Gardner B, et al. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124(5):978-84.|[2]Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406(1-2):33-6.|[3]Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4.|[4]Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35(1):90-7.|[5]Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11.BMC Endocr Disord. 2021 Nov 23;21(1):235.|Br J Pharmacol. 2021 Apr 26.|Eur J Integr Med. 2021, 101322.|Eur J Pharmacol. 2022: 175443.|Int J Mol Sci. 2024 Nov 21;25(23):12483.|J Biomol Struct Dyn. 2021 Sep 22;1-12.|J Endocrinol Invest. 2024 Jun 26.|J Ethnopharmacol. 2021 Mar 9;113994.|Nat Commun. 2020 Feb 18;11(1):941. |Sci Adv. 2021 Nov 26;7(48):eabj4624.|Mol Pharm. 2022 Oct 21.|Pharmacogn Mag. 2023 Oct 12.|Toxicol Appl Pharmacol. 2024 Mar 2:116876.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched